Strengthening the Reporting of Genetic Risk Prediction Studies: The GRIPS Statement

1. KhouryMJ

GwinnM

YoonPW

DowlingN

MooreCA

2007 The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention? Genet Med 9 665 674

2. HlatkyMA

GreenlandP

ArnettDK

BallantyneCM

CriquiMH

2009 Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119 2408 2416

3. KyzasPA

Denaxa-KyzaD

IoannidisJP

2007 Quality of reporting of cancer prognostic marker studies: association with reported prognostic effect. J Natl Cancer Inst 99 236 243

4. KyzasPA

LoizouKT

IoannidisJP

2005 Selective reporting biases in cancer prognostic factor studies. J Natl Cancer Inst 97 1043 1055

5. McShaneLM

AltmanDG

SauerbreiW

TaubeSE

GionM

2005 REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Urol 2 416 422

6. KyzasPA

Denaxa-KyzaD

IoannidisJP

2007 Almost all articles on cancer prognostic markers report statistically significant results. Eur J Cancer 43 2559 2579

7. TzoulakiI

LiberopoulosG

IoannidisJP

2009 Assessment of claims of improved prediction beyond the Framingham risk score. JAMA 302 2345 2352

8. von ElmE

EggerM

2004 The scandal of poor epidemiological research. BMJ 329 868 869

9. SimeraI

MoherD

HoeyJ

SchulzKF

AltmanDG

2010 A catalogue of reporting guidelines for health research. Eur J Clin Invest 40 35 53

10. von ElmE

AltmanDG

EggerM

PocockSJ

GotzschePC

2007 The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 4 e296 doi:10.1371/journal.pmed.0040296

11. LittleJ

HigginsJP

IoannidisJP

MoherD

GagnonF

2009 STrengthening the REporting of Genetic Association Studies (STREGA): an extension of the STROBE statement. PLoS Med 6 e22 doi:10.1371/journal.pmed.1000022

12. BossuytPM

ReitsmaJB

BrunsDE

GatsonisCA

GlasziouPP

2003 Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. BMJ 326 41 44

13. McShaneLM

AltmanDG

SauerbreiW

TaubeSE

GionM

2005 Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 23 9067 9072

14. JanssensACJW

Van DuijnCM

2009 Genome-based prediction of common diseases: methodological considerations for future research. Genome Med 1 20

15. KhouryMJ

GwinnM

IoannidisJP

2010 The emergence of translational epidemiology: from scientific discovery to population health impact. Am J Epidemiol 172 517 524

16. MoonsKG

AltmanDG

VergouweY

RoystonP

2009 Prognosis and prognostic research: application and impact of prognostic models in clinical practice. BMJ 338 b606

17. KhouryMJ

DormanJS

1998 The Human Genome Epidemiology Network. Am J Epidemiol 148 1 3

18. FreedmanAN

SeminaraD

GailMH

HartgeP

ColditzGA

2005 Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst 97 715 723

19. AltmanDG

SchulzKF

MoherD

EggerM

DavidoffF

2001 The revised CONSORT statement for reporting randomized trials: explanation and elaboration. Ann Intern Med 134 663 694

20. BossuytPM

ReitsmaJB

BrunsDE

GatsonisCA

GlasziouPP

2003 The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration. Ann Intern Med 138 W1 12

21. LiberatiA

AltmanDG

TetzlaffJ

MulrowC

GotzschePC

2009 The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 6 e1000100 doi:10.1371/journal.pmed.1000100

22. VandenbrouckeJP

von ElmE

AltmanDG

GotzschePC

MulrowCD

2007 Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 4 e297 doi:10.1371/journal.pmed.0040297

23. VandenbrouckeJP

2009 STREGA, STROBE, STARD, SQUIRE, MOOSE, PRISMA, GNOSIS, TREND, ORION, COREQ, QUOROM, REMARK... and CONSORT: for whom does the guideline toll? J Clin Epidemiol 62 594 596

24. CookNR

2007 Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation 115 928 935

25. PencinaMJ

D'AgostinoRBSr

D'AgostinoRBJr

VasanRS

2008 Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27 157 172

26. JanssensACJW

KhouryMJ

2010 Assessment of improved prediction beyond traditional risk factors: when does a difference make a difference? Circ: Cardiovasc Genet 3 3 5